187 related articles for article (PubMed ID: 20683492)
21. Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.
Gavrilov K; Seo YE; Tietjen GT; Cui J; Cheng CJ; Saltzman WM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):E6597-605. PubMed ID: 26627251
[TBL] [Abstract][Full Text] [Related]
22. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
Zhang JH; He YL; Zhu R; Du W; Xiao JH
Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
[TBL] [Abstract][Full Text] [Related]
23. Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-
Singh A; Bhatia P
Curr Gene Ther; 2021; 21(3):270-277. PubMed ID: 33596804
[TBL] [Abstract][Full Text] [Related]
24. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
Bártová E; Harnicarová A; Pacherník J; Kozubek S
Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
[TBL] [Abstract][Full Text] [Related]
25. miRNA143 Induces K562 Cell Apoptosis Through Downregulating BCR-ABL.
Liang B; Song Y; Zheng W; Ma W
Med Sci Monit; 2016 Aug; 22():2761-7. PubMed ID: 27492780
[TBL] [Abstract][Full Text] [Related]
26. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
Scherr M; Chaturvedi A; Battmer K; Dallmann I; Schultheis B; Ganser A; Eder M
Blood; 2006 Apr; 107(8):3279-87. PubMed ID: 16278304
[TBL] [Abstract][Full Text] [Related]
27. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
[TBL] [Abstract][Full Text] [Related]
28. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.
Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH
Clin Exp Med; 2007 Jun; 7(2):47-55. PubMed ID: 17609876
[TBL] [Abstract][Full Text] [Related]
30. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
[TBL] [Abstract][Full Text] [Related]
31. [Experimental study of K562 cell apoptosis induced by siRNA].
Chen BB; Fan HH; Lin GW; Yuan ZH; Lu HZ; Gao L; Liu Y
Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):717-9. PubMed ID: 15730712
[TBL] [Abstract][Full Text] [Related]
32. [Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression].
Ma XX; Wang C; Wei J; Qin YW; Yan SK; Gao YR; Cai Q
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):359-62. PubMed ID: 16185484
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
34. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Withey JM; Harvey AJ; Crompton MR
Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
[TBL] [Abstract][Full Text] [Related]
35. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
36. [Effect of silencing bmi-1 by RNA interference on function of K562 cell line].
Chen XL; Ren Q; Chen ZP; Zhou ZP; Zhao QJ; Qiu ZY; Dong CL; Han ZC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):266-70. PubMed ID: 19379548
[TBL] [Abstract][Full Text] [Related]
37. [Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo].
Zhu YF; Wang YZ; Meng FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1090-4. PubMed ID: 23114125
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
Koldehoff M; Elmaagacli AH
Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661
[TBL] [Abstract][Full Text] [Related]
39. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
[TBL] [Abstract][Full Text] [Related]
40. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
